Inflammatory Basis of Pulmonary Arterial Hypertension-Reference-Cited by-同舟云学术

Inflammatory Basis of Pulmonary Arterial Hypertension

Published:2019-10-01 Issue:4 Volume:131 Page:898-907
ISSN:0003-3022
Container-title:Anesthesiology
language:en
Short-container-title:

Author:

Goldenberg Neil M.¹,Rabinovitch Marlene¹,Steinberg Benjamin E.¹

Affiliation:

1. From the Department of Anesthesia and Pain Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada (N.M.G., B.E.S.); Sick Kids Research Institute, Program in Cell Biology (N.M.G.) and Program in Neuroscience and Mental Health (B.E.S.), Toronto, Ontario, Canada; Department of Pediatrics and Vera Moulton Wall Center for Pulmonary Vascular Disease, Stanford University School of Medicine,

Abstract

Patients with pulmonary arterial hypertension have exceptionally high perioperative risk. This review summarizes the clinical presentation and therapies for pulmonary arterial hypertension, and it highlights evidence for inflammation as a driver of disease pathogenesis and a therapeutic target.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Anesthesiology and Pain Medicine

Link

http://pubs.asahq.org/anesthesiology/article-pdf/131/4/898/460774/20191000_0-00032.pdf

Reference71 articles.

1. Updated clinical classification of pulmonary hypertension.;J Am Coll Cardiol,2013

2. Pulmonary arterial hypertension: Pathogenesis and clinical management.;BMJ,2018

3. The right ventricle explains sex differences in survival in idiopathic pulmonary arterial hypertension.;Chest,2014

4. Pulmonary arterial hypertension: Baseline characteristics from the REVEAL Registry.;Chest,2010

5. Effect of breathing oxygen-enriched air on exercise performance in patients with precapillary pulmonary hypertension: Randomized, sham-controlled cross-over trial.;Eur Heart J,2017

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regioselective Annulation of 3(5)‐Aminopyrazole with Aryl Ketones or Aryl Alkynes Using N,N‐Dimethylethanolamine as a Single/Triple Carbon Synthon;Advanced Synthesis & Catalysis;2024-08-05

2. Emerging therapies: Potential roles of SGLT2 inhibitors in the management of pulmonary hypertension;Respiratory Medicine;2024-06

3. NLRP3 Inflammasome: A Novel Mediator in Pulmonary Hypertension;The NLRP3 Inflammasome: An Attentive Arbiter of Inflammatory Response;2024-04-02

4. Human umbilical cord mesenchymal stromal cell-derived exosomes alleviate hypoxia-induced pulmonary arterial hypertension in mice via macrophages;Stem Cells;2023-12-28

5. Therapeutic effects of hypoxia-preconditioned bone marrow-derived mesenchymal stromal cells and their extracellular vesicles in experimental pulmonary arterial hypertension;Life Sciences;2023-09